Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06897527 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Feb 13, 2026 to Jan 13, 2027
    • Start date: Apr 17, 2025 to Jul 15, 2025
    • Study completion date: Jun 1, 2026 to Jan 13, 2027
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
Trial Details
NCT Number NCT06897527
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Neoplasms, Endometrial
Related terms Endometrial Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov